1[1]Cohn JN,Johnson GR,Shabetai R,et al. Ejection fraction,peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias and plasma norepinephrine as determinants of prognosis in heart failure[J]. Circulation,1993,87(supple VI ): Ⅵ 5-16
2[2]The SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial[J]. N Engl J Med, 1992,327:669-677
3[3]MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congesitve Heart Failure (MERIT-HF) [J]. Lancet, 1999,353: 2001-2007
4[4]Packer M. The neurohormonal hypothesis:a theory to explain the mechanism of disease progression in heart failure [J]. J Am Coll Cardiol, 1992,20: 248-254
5[5]Hjalmarson A,Waagstein F. The role of β-blockers in the treatment of car diomyopathy and ischaemic heart failure[J ]. Drugs, 1994,47 (Suppl 4 ): 31- 37
6[6]Daly PA,Sole MJ. Myocardial catecholamines and the pathophysiology of heart failure[J]. Circulation, 1990,82(suppl 1):I35-I43
7[7]Esler M,Kaye D,Lambert G,et al. Adrenergic Nervous System in heart failure[J]. Am J Cardiol,1997,80(11A):7L-14L
8[8]Hasking GJ,Esler MD,Jennings GI,et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity[J]. Circulation, 1986,73:615-621
9[9]Henderson EB,Kahn JK,Corbett JR,et al. Abnormal I123 metaiodoben zylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive heart failure[J]. Circula tion, 1988,78:1192-1199
10[10]Konstam MA,Rousseau MF,Kronenberg MW,et al. Effects of the angiotensin converting enzyme inhibitor,enalapril.on the long term progression of left ventricular dysfunction in patients with heart failure[J]. Circulation, 1992,86: 431-438
